2nd Quarter - Report

BOSTON SCIENTIFIC CORPORATION for BOSTON SCIENTIFIC CORPORATION

Firm
Client
Income
—
Expenses
$410,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

Limitations on aircraft transportation of lithium batteries H.R. 4 and S. 1405 - Federal Aviation Administration Re-authorization Act of 2018 - Limitations on aircraft transportation of lithium batteries (House & Senate)

LobbyistCovered position, as disclosed
BRENDA BECKER —
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1405 (115th), H.R. 4 (115th)

Health Issues HCR

Public Law 115-52 FDA Reauthorization Act of 2017- specifically pertaining to user fees used to train FDA staff and streamline approval process Unique Device Identifiers (UDI) - Implementation of UDI rule HR5997 - Ensuring Patient Access to Critical Breakthrough Products Act FDA/CMS Breakthrough Pathway - Legislation to harmonize CMS Reimbursement with FDA Approval to speed products' market introduction House/Senate Implementation of Comprehensive Addiction & Recovery Act (CARA) Law to address the National Opioid epidemic. Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain S1656- Cyber Security for Medical Devices S1691- Internet of Things Cyber Security Improvement Act of 2017-Specifically regarding Medical Devices HR3985- Recommended voluntary frameworks and guidelines to increase security of Internet of Things Medical Devices Working draft of Comprehensive Addiction & Recovery Act 2.0 (CARA 2.0) to address the National Opioid epidemic. Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain House & Senate Opioid Legislation: OCRA and other HELP Bills, E&C Bills, W&M bills, Senate Finance Bills aimed at addressing the national opioid epidemic; specifically the role of FDA approved alternative treatments for Chronic pain and opioid abuse. HR6 -Substance Use-Disorder Prevention that Promises Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act - Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain S2680 - Opioid Crisis Response Act (OCRA) - Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain S3120 - Helping to End Addiction & Lessen Substance Abuse Disorders Act (HEAL Act) - Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain S2891 - Fighting the Opioid Epidemic with Sunshine Act of 2018(Sunshine Expansion Act) - Specifically, transparency and medical device's role in the opioid epidemic.

LobbyistCovered position, as disclosed
BRENDA BECKER —
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5997 (115th), H.R. 6 (115th), H.R. 3985 (115th)

Veterans VET

VHA Directive 2009-053 - Pain care directive - working to increase veteran access to pain specialists and FDA approved alternative treatments in the VHA Public Law No. 113-146 - Veterans Access, Choice, and Accountability Act: Implementation of law to allow veterans to seek healthcare from non-VA facilities if unable to receive care from the VA in a timely manner. National Pain Strategy - Encouraging adaption of the NIH's National Pain Strategy Medial device supply chain procurement - VHA patient access to Med Technology as VHA migrates to new sourcing methodology Implementation of Comprehensive Addiction and Recovery Act (CARA) law to improve the quality of Pain Care provided to veterans. Purchase Order Prompt Pay - Ensures the VA pays bills in accordance with the law. HR5418 - VA Medsurg Purchasing Stabilization Act

LobbyistCovered position, as disclosed
BRENDA BECKER —
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5418 (115th)

Budget/Appropriations BUD

Public Law No: 113-67 - Making continuing appropriations for fiscal year 2014 and for other purposes. Specifically provisions providing appropriations for the FDA's CDRH evaluation of medical technology. FY 2019 Agriculture Appropriations Bill (House) - FDA Funding FY 2019 Agriculture Appropriations Bill (Senate) - FDA Funding FY 2019 Labor HHS Appropriations Bill (House) - Collection of Pain Care Statistics FY 2019 Labor HHS Appropriations Bill (Senate) - Collection of Pain Care Statistics

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

North American Free Trade Agreement (NAFTA) - Supporting passage of updated agreement to reflect current trade investment environment for Medical Devices Countries specific market access issues - India price controls and China market access issues Tariffs

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Public Law 115-97 - Implementation of Comprehensive/Corporate Tax Reform - Includes lower corporate tax rate, research credit transition, base erosion, International Tax Reform Provisions, and tax Extender Provisions S108 & HR 184 - Legislation to repeal the 2.3% Medical Device Tax

LobbyistCovered position, as disclosed
BRENDA BECKER —
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 184 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.